# Extensive-stage Small Cell Lung Cancer FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/extensive-stage-small-cell-lung-cancer

> 8 upcoming FDA catalysts in extensive-stage Small Cell Lung Cancer: bms-986489 (atigotatug+nivolumab, BMY) on Aug to Nov 2027 (topline data readout); bms-986489 (atigotatug+nivolumab, BMY) on August 2027 (primary completion); pumitamig (BNTX) on April 2029 (primary completion); pumitamig (BNTX) on Apr to Jul 2029 (topline data readout); and 4 more.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| May 22, 2025 | [Opdivo® (nivolumab) primary completion](https://sec-api.dev/pdufa/nivolumab) | BMY | Extensive-stage Small Cell Lung Cancer | completed | "NCT04702880 (A Study of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-05-22 (ACTUAL); Lead Sponsor Bristol-Myers Squibb; Results First Posted 2026-06-17." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04702880)) |
| June 17, 2026 | [Opdivo® (nivolumab) topline data readout](https://sec-api.dev/pdufa/nivolumab) | BMY | Extensive-stage Small Cell Lung Cancer | completed | "NCT04702880 (A Study of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-05-22 (ACTUAL); Lead Sponsor Bristol-Myers Squibb; Results First Posted 2026-06-17." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04702880?tab=results)) |
| Aug to Nov 2027 | [Bms-986489 (atigotatug+nivolumab) topline data readout](https://sec-api.dev/pdufa/bms-986489-atigotatug-nivolumab) | BMY | Extensive-Stage Small Cell Lung Cancer | scheduled | "NCT06646276 (A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-08-17 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06646276)) |
| August 2027 | [Bms-986489 (atigotatug+nivolumab) primary completion](https://sec-api.dev/pdufa/bms-986489-atigotatug-nivolumab) | BMY | Extensive-Stage Small Cell Lung Cancer | scheduled | "NCT06646276 (A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-08-17 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06646276)) |
| April 2029 | [Pumitamig primary completion](https://sec-api.dev/pdufa/pumitamig) | BNTX | Extensive-stage Small-cell Lung Cancer | scheduled | "NCT06712355 (Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-04 (ESTIMATED); Lead Sponsor BioNTech SE." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06712355)) |
| Apr to Jul 2029 | [Pumitamig topline data readout](https://sec-api.dev/pdufa/pumitamig) | BNTX | Extensive-stage Small-cell Lung Cancer | scheduled | "NCT06712355 (Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-04 (ESTIMATED); Lead Sponsor BioNTech SE." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06712355)) |
| Aug to Nov 2029 | [Zepzelca (lurbinectedin) topline data readout](https://sec-api.dev/pdufa/lurbinectedin) | JAZZ | Extensive-stage Small-cell Lung Cancer | scheduled | "NCT07459634 (A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-08-04 (ESTIMATED); Lead Sponsor Jazz Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07459634)) |
| August 2029 | [Zepzelca (lurbinectedin) primary completion](https://sec-api.dev/pdufa/lurbinectedin) | JAZZ | Extensive-stage Small-cell Lung Cancer | scheduled | "NCT07459634 (A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-08-04 (ESTIMATED); Lead Sponsor Jazz Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07459634)) |
| Jun to Sep 2030 | [Zl-1310 in combination with atezolizumab or durvalumab topline data readout](https://sec-api.dev/pdufa/zl-1310-in-combination-with-atezolizumab-or-durvalumab) | ZLAB | Extensive-Stage Small Cell Lung Cancer | scheduled | "NCT07796100 (A Study of ZL-1310 in Combination With a Checkpoint Inhibitor Versus Standard of Care Platinum Based Chemotherapy With a Checkpoint Inhibitor as First-line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2030-06-30 (ESTIMATED); Lead Sponsor Zai Lab (Shanghai) Co., Ltd.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07796100)) |
| June 2030 | [Zl-1310 in combination with atezolizumab or durvalumab primary completion](https://sec-api.dev/pdufa/zl-1310-in-combination-with-atezolizumab-or-durvalumab) | ZLAB | Extensive-Stage Small Cell Lung Cancer | scheduled | "NCT07796100 (A Study of ZL-1310 in Combination With a Checkpoint Inhibitor Versus Standard of Care Platinum Based Chemotherapy With a Checkpoint Inhibitor as First-line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2030-06-30 (ESTIMATED); Lead Sponsor Zai Lab (Shanghai) Co., Ltd.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07796100)) |

## Drugs

- [Opdivo® (nivolumab)](https://sec-api.dev/pdufa/nivolumab) (BMY)
- [Bms-986489 (atigotatug+nivolumab)](https://sec-api.dev/pdufa/bms-986489-atigotatug-nivolumab) (BMY)
- [Pumitamig](https://sec-api.dev/pdufa/pumitamig) (BMY)
- [Zepzelca (lurbinectedin)](https://sec-api.dev/pdufa/lurbinectedin) (JAZZ)
- [Zl-1310 in combination with atezolizumab or durvalumab](https://sec-api.dev/pdufa/zl-1310-in-combination-with-atezolizumab-or-durvalumab) (ZLAB)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/extensive-stage-small-cell-lung-cancer.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Extensive-stage Small Cell Lung Cancer FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/extensive-stage-small-cell-lung-cancer

```bibtex
@misc{secapidev_indications_extensive_stage_small_cell_lung_cancer_20261116,
  title        = {Extensive-stage Small Cell Lung Cancer FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/extensive-stage-small-cell-lung-cancer}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_extensive_stage_small_cell_lung_cancer_20261116","title":"Extensive-stage Small Cell Lung Cancer FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/extensive-stage-small-cell-lung-cancer","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
